Huan Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huan Gong has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Marcus Laird Forrest
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
6 shared publications - Moustafa M. Abdelaziz
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
5 shared publications - Cory Berkland
Washington University in St. Louis
4 shared publications - Chad Groer
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
2 shared publications - Christian Schöneich
Department of Pharmaceutical Chemistry, University of Kansas, 2093 Constant Avenue, Lawrence, Kansas 66047, United States
2 shared publications David S. Richards
2 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (12)
Impact of oxidative degradation on the bioavailability of subcutaneously administered adalimumab
- 17 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (12)
Open AccessImpact of oxidative degradation on the bioavailability of subcutaneously administered adalimumab
- 29 September 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5596-5608
Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors
Glatiramer acetate (GA) is a heterogeneous mixture of peptides that we have previously explored as an intratumoral immunomodulator. However, its chemical complexity complicates the mechanistic interpretation and rational design. In this study, we evaluated a set of sequence-defined “glatiramoid” peptides engineered to preserve the amino acid composition while varying the primary sequence. Biophysical characterization by circular dichroism, fluorescence spectroscopy, and transmission electron microscopy revealed sequence-dependent differences in supramolecular organization without pronounced changes in the secondary structure. Treatment of murine bone marrow-derived dendritic cells with these peptides produced distinct innate cytokine and chemokine secretion profiles, suggesting that sequence order influences immune signaling outcomes in vitro. In the CT26 mouse model of colon carcinoma, intratumoral administration of selected glatiramoid peptides in combination with anti-PD-1 therapy produced tumor growth responses that were not statistically distinguishable from those of commercial GA formulations. Systemic cytokine levels measured at study termination were generally lower for the sequence-defined peptide relative to GA. Together, these findings indicate that sequence-defined glatiramoid peptides reproduce selected GA-like biophysical and immunomodulatory properties. Further studies are required to establish their mechanisms of action, intratumoral behavior, and therapeutic contribution to checkpoint blockade.
- 29 September 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5596-5608
Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors
Glatiramer acetate (GA) is a heterogeneous mixture of peptides that we have previously explored as an intratumoral immunomodulator. However, its chemical complexity complicates the mechanistic interpretation and rational design. In this study, we evaluated a set of sequence-defined “glatiramoid” peptides engineered to preserve the amino acid composition while varying the primary sequence. Biophysical characterization by circular dichroism, fluorescence spectroscopy, and transmission electron microscopy revealed sequence-dependent differences in supramolecular organization without pronounced changes in the secondary structure. Treatment of murine bone marrow-derived dendritic cells with these peptides produced distinct innate cytokine and chemokine secretion profiles, suggesting that sequence order influences immune signaling outcomes in vitro. In the CT26 mouse model of colon carcinoma, intratumoral administration of selected glatiramoid peptides in combination with anti-PD-1 therapy produced tumor growth responses that were not statistically distinguishable from those of commercial GA formulations. Systemic cytokine levels measured at study termination were generally lower for the sequence-defined peptide relative to GA. Together, these findings indicate that sequence-defined glatiramoid peptides reproduce selected GA-like biophysical and immunomodulatory properties. Further studies are required to establish their mechanisms of action, intratumoral behavior, and therapeutic contribution to checkpoint blockade.
- Open Access
- 17 February 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 222, 115025
Magnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples
- 17 February 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 222, 115025
Open AccessMagnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples
- 7 February 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 692, 126659
Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths
- 7 February 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 692, 126659
Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths
- Open Access
- 28 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
Development of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes
- 28 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
Open AccessDevelopment of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes
- Open Access
- 17 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Lyophilized Formulation Development and Characterization of Stable Glatiramer Acetate/Oligonucleotide Polyplexes at Clinically Therapeutic Strengths
Glatiramer acetate (GA) electrostatically complexes with cytosine-guanine oligodeoxynucleotides (CpG ODN) forming ~100 nm cationic nanoparticles that localize this potent immunostimulant to the injection site. We previously reported GA-CpG nanoparticles retained the anti-tumor activity of CpG while mitigating systemic immune-related adverse events. Nonetheless, nanoparticulate systems like polypeptide-oligonucleotide complexes pose challenges with reproducible production, in-use stability, and storage stability which must be solved before translation for clinical use. In this study, we systematically investigated a microfluidic mixing process to define reproducible production of GA-CpG nanoparticles. Dynamic light scattering measurements revealed significantly smaller and more uniform nanoparticles for microfluidic processing versus traditional mixing via pipette. Next, we screened a range of buffer systems to determine the pH and ion types that could maintain colloidal stability and CpG potency. Buffer screening tests indicated that amino acid buffers, particularly glutamic acid, better maintained particle consistency than commonly used parenteral buffers. Finally, formulations of potential lyoprotectants and GA-CpG nanoparticles were developed. Freeze-thaw and freeze-drying experiments were conducted to assess the effects of buffers and lyoprotectants. Formulations with 5% HP-β-CD or trehalose yielded mean particle sizes of less than 127 nm and retained even after storage for 6 months at 40 °C/75% relative humidity. The work on electrostatic complexes reported here may provide valuable guidance to formulators aiming to optimize polypeptide-based oligonucleotide polyplex products.
- 17 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessLyophilized Formulation Development and Characterization of Stable Glatiramer Acetate/Oligonucleotide Polyplexes at Clinically Therapeutic Strengths
Glatiramer acetate (GA) electrostatically complexes with cytosine-guanine oligodeoxynucleotides (CpG ODN) forming ~100 nm cationic nanoparticles that localize this potent immunostimulant to the injection site. We previously reported GA-CpG nanoparticles retained the anti-tumor activity of CpG while mitigating systemic immune-related adverse events. Nonetheless, nanoparticulate systems like polypeptide-oligonucleotide complexes pose challenges with reproducible production, in-use stability, and storage stability which must be solved before translation for clinical use. In this study, we systematically investigated a microfluidic mixing process to define reproducible production of GA-CpG nanoparticles. Dynamic light scattering measurements revealed significantly smaller and more uniform nanoparticles for microfluidic processing versus traditional mixing via pipette. Next, we screened a range of buffer systems to determine the pH and ion types that could maintain colloidal stability and CpG potency. Buffer screening tests indicated that amino acid buffers, particularly glutamic acid, better maintained particle consistency than commonly used parenteral buffers. Finally, formulations of potential lyoprotectants and GA-CpG nanoparticles were developed. Freeze-thaw and freeze-drying experiments were conducted to assess the effects of buffers and lyoprotectants. Formulations with 5% HP-β-CD or trehalose yielded mean particle sizes of less than 127 nm and retained even after storage for 6 months at 40 °C/75% relative humidity. The work on electrostatic complexes reported here may provide valuable guidance to formulators aiming to optimize polypeptide-based oligonucleotide polyplex products.
- 1 November 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6323-6338
Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) have a storied history as agonists for Toll-like receptor 9 (TLR9). CpG ODNs have shown promising antitumor effects in preclinical studies by inducing potent proinflammatory immune responses. However, clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure to CpG ODNs. We previously identified that glatiramer acetate (GA), an FDA-approved, lysine-rich polypeptide, could complex class B CpG into cationic nanoparticles which persist at the intratumoral injection site while mitigating the induction of systemic proinflammatory cytokines in mouse tumor models. To extend GA applications across subtypes of CpG ODN (class A, B, and C), we evaluated physiochemical properties and identified the immunological signaling of GA and its complexes with different classes of CpG ODNs. We compared the physiochemical characteristics of three types of GA-CpG nanoparticles, followed by assessments of cell uptake efficiency and endolysosomal trafficking. We then performed successive in vitro and in vivo assays to evaluate immunological discrepancies. Complexation with GA preserved the immunological activity of CpG ODN subtypes while encapsulating them into cationic spherical nanoparticles. GA improved the cellular uptake of CpG ODNs, generally increased retention in early endosomes, and amplified immunological responses. A subsequent in vivo experiment confirmed the achievement of potent tumor suppression while mitigating systemic immune-related toxicities. Together, these data help elucidate the noncanonical role of GA to serve as a nucleic acid delivery scaffold that can improve the efficacy and safety of CpG adjuvant for clinical cancer immunotherapy.
- 1 November 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6323-6338
Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) have a storied history as agonists for Toll-like receptor 9 (TLR9). CpG ODNs have shown promising antitumor effects in preclinical studies by inducing potent proinflammatory immune responses. However, clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure to CpG ODNs. We previously identified that glatiramer acetate (GA), an FDA-approved, lysine-rich polypeptide, could complex class B CpG into cationic nanoparticles which persist at the intratumoral injection site while mitigating the induction of systemic proinflammatory cytokines in mouse tumor models. To extend GA applications across subtypes of CpG ODN (class A, B, and C), we evaluated physiochemical properties and identified the immunological signaling of GA and its complexes with different classes of CpG ODNs. We compared the physiochemical characteristics of three types of GA-CpG nanoparticles, followed by assessments of cell uptake efficiency and endolysosomal trafficking. We then performed successive in vitro and in vivo assays to evaluate immunological discrepancies. Complexation with GA preserved the immunological activity of CpG ODN subtypes while encapsulating them into cationic spherical nanoparticles. GA improved the cellular uptake of CpG ODNs, generally increased retention in early endosomes, and amplified immunological responses. A subsequent in vivo experiment confirmed the achievement of potent tumor suppression while mitigating systemic immune-related toxicities. Together, these data help elucidate the noncanonical role of GA to serve as a nucleic acid delivery scaffold that can improve the efficacy and safety of CpG adjuvant for clinical cancer immunotherapy.